Login / Signup

Ferumoxytol: an emerging therapeutic for iron deficiency anemia.

Midori SakashitaMasaomi Nangaku
Published in: Expert opinion on pharmacotherapy (2022)
There is substantial evidence that ferumoxytol is effective for the treatment of IDA. The efficacy of ferumoxytol in improving anemia is comparable to that of iron sucrose and ferric carboxymaltose (FCM) and superior to that of oral iron or a placebo in replenishing iron stores. Treatment with ferumoxytol, although more expensive, is cost-effective for outpatients requiring parenteral administration because it requires fewer doses and shorter dosing times per dose. Ferumoxytol also causes less frequent hypophosphatemia than FCM. Currently, its use in children and pregnant women is under consideration, which may provide important information for the future applications of ferumoxytol in larger numbers of patients.
Keyphrases
  • iron deficiency
  • pregnant women
  • end stage renal disease
  • chronic kidney disease
  • newly diagnosed
  • young adults
  • ejection fraction
  • randomized controlled trial
  • healthcare
  • combination therapy
  • prognostic factors